- Capital Cube•20 hours ago
Click here to see latest analysisNovartis AG reports financial results for the quarter ended June 30, 2016.We analyze the earnings along side the following peers of Novartis AG – Johnson & Johnson and Abbott Laboratories (JNJ-US and ABT-US) that have also reported for this period.HighlightsSummary numbers: Revenues of USD 12,522.42 million, Net Earnings of USD […] (Read more...) The post Novartis AG :NVS-US: Earnings Analysis: Q2, 2016 By the Numbers : July 26, 2016 appeared first on CapitalCube.
We keep the tough going with 2,300 convenient locations, 6,500 helpful employees & a 97% customer satisfaction rating. Talk about strength in numbers.
- Market Realist•22 hours ago
Novartis’s current valuation is neither high nor low. During the past five years, Novartis’s PE multiple has ranged from ~9x to ~20x.
After hours: 83.280.26 (0.31%) as of 5:16 PM EDT
|Bid||82.56 x 3500|
|Ask||82.64 x 3900|
|52wk Range||69.90 - 104.75|
|Day's Range||82.85 - 83.48|
|Avg Vol (3m)||1,831,252|
As of 4:02 PM EDT. Market closed.